Salicylates inhibit NF-κB activation and enhance TNF-α-induced apoptosis in human pancreatic cancer cells

Journal of Surgical Research

Volumn 83, Issue 1, 1999, Pages 56-61

  McDade, Theodore P ^a   Perugini, Richard A ^a   Vittimberga Jr , Frank J ^a   Carrigan, Rebecca C ^a   Callery, Mark P ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Nuclear factor kappa B (NF B); Pancreatic cancer; Sodium salicylate; Tumor necrosis factor alpha (TNF )

Indexed keywords

DNA FRAGMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SALICYLATE SODIUM; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; STAINING;

EID: 0033134106     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5560     Document Type: Conference Paper

References (31)

1. Parker S. L. Cancer statistics, 1997. Cancer J. Clinicians. 47:1997;5.
2. Yeo C. J. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. Anna. Surg. 225:1997;621.
3. Coley W. B. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. 5:1893;487.
4. O'Malley W. E., Achinstein B., Shear M. J. Action by bacterial polysaccharide on tumors. J. Natl. Cancer. 29:1962;1169.
5. Carswell E. A. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA. 72:1975;3666.
6. Beutler B. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature. 316:1985;552.
7. Beutler B. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 161:1985;984.
8. Pennica D. Human tumour necrosis factor: Precursor structure, expression, and homology to lymphotoxin. Nature. 312:1984;724.
9. Brophy L. Tumor necrosis factor. Biotherapy: A Comprehensive Overview. 1995;Jones and Bartlett, Boston. p. 161-176.
10. Beg A. A., Baltimore D. An essential role for NF-κB in preventing TNF-α induced cell death. Science. 274:1996;782.
11. Wang C. Y., Mayo M. W., Baldwin A. S. Jr. TNF and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science. 274:1996;784.
12. Van Antwerp D. J. Suppression of TNF-α induced apoptosis by NF-κB. Science. 274:1996;787.
13. Schwenger P. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκBα phosphorylation and degradation. Mol. Cell. Biol. 18:1998;78.
14. Kopp E., Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 265:1994;956.
15. McDade T. P. Sodium salicylate inhibits tumor necrosis factor-induced IκB-α phosphorylation and degradation in human pancreatic cancer. Owen H. Wangensteen Surg. Forum. 49:1998;438.
16. Schwenger P. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA. 94:1996;2869.
17. Dignam J. D., Lebovitz R. M., Roeder R. G. Accurate transcription initiation by polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475.
18. Elder D. E. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res. 56:1996;2273.
19. Trujillo M. A., Garewal H. S., Sampliner R. E. Non-steroidal antiinflammatory agents in chemoprevention of colorectal cancer. At what cost. Dig. Dis. Sci. 39:1994;2260.
20. Giardiello F. M., Offerhaus G. J. A., DuBois R. N. The role of non-steroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J. Cancer. 31A:1995;1071.
21. Perugini R. A. The molecular and cellular biology of pancreatic cancer. Crit. Rev. Eukaryotic Gene Expression. 8:1998;377.
22. Berrozpe G. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int. J. Cancer. 58:1994;185.
23. Naumann M. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in human pancreatic cancer. Gastroenterology. 110:1996;1215.
24. Barton C. M. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer. 64:1991;1076.
25. Sen R., Baltimore D. Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell. 47:1986;921.
26. Finco T. S., Beg A. A., Baldwin A. S. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. 91:1994;11884.
27. Schmitz M. L., Baeuerle P. A. Multi-step activation of NF-κB/Rel transcription factors. Immunobiology. 193:1995;116.
28. Beauparlant P., Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 7:1996;175.
29. Brown A. Function of NF-κB/Rel binding sites in the major histocompatability complex class II invariant chain promoter is dependent on cell-specific binding of different NK-κB/Rel subunits. Mol. Cell. Biol. 14:1994;2926.
30. Kang S. NF-κB subunit regulation in nontransformed CD4+ T lymphocytes. Science. 256:1992;1452.
31. Mauceri H. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature. 394:1998;287.